The Public Cannabis Company Revenue Tracker, managed by New Cannabis Ventures, ranks the top revenue producing cannabis stocks that generate industry sales of more than US$2.5 million per quarter. This data-driven, fact-based tracker will continually update based on new filings so that readers can stay up to date. Companies must file with the SEC or SEDAR to be considered for inclusion.

Nineteen companies currently qualify for inclusion, with eight filing in U.S dollars and eleven in the Canadian currency. Since our last update, three public companies qualified for inclusion and have been added to the list, including newly public Green Thumb Industries (CSE: GTII) (OTC: GTBIF) and MedMen Enterprises (CSE: MMEN) (OTC: MMNFF). Both companies file in U.S. dollars, though their primary listing is in Canada.

In mid-June, MedReleaf (TSX: LEAF) (OTC: MEDFF) reported what will likely be its last quarter as a stand-alone company, as it is being acquired by Aurora Cannabis (TSX: ACB) (OTC: ACBFF). On a combined basis, the two companies would be the leader in terms of revenue for the sector. Sales in its fiscal Q4 ending March 31 grew 16% from year-ago levels, but, at C$12 million, were about 5% below the consensus estimate. In the late June, Canopy Growth (TSX: WEED) (NYSE: CGC) reported sales for its fiscal Q4 ending March 31 of almost C$23 million, up 55% from a year ago and up 5% from the prior quarter. The results fell about 8% below the consensus forecast. Additionally, Friday Night (CSE: TGIF) (OTC: TGIFF), which is listed in Canada and reports in Canadian dollars but operates in the United States, reported its fiscal Q3 ending April 30th, with sales right at the level required to qualify for inclusion. The company’s C$3.32 million in sales grew 12% from Q2 levels, split between its Nevada cultivation and production operations (C$2.03 million), its hemp-based CBD products (C$1.19 million) and its security operations (C$0.28 million)

In July, several companies are scheduled to provide financial updates. Isodiol International (CSE: ISOL) (OTC: ISOLF) will provide financials for its fiscal Q4 ending March 31 by July 30th. In mid-July, Kush Bottles (OTC: KSHB) will provide financials for its fiscal Q3 ending May 31, with the consensus estimate according to Sentieo at $12.04 million, which would represent annual growth of 155%. MPX Bioceutical (CSE: MPX) (OTC: MPXEF) will provide financials for its fiscal Q4 ending March 31 by the end of July, but the company indicated in a recent conference call that it expects to provide them in early July. According to Sentieo, the analyst covering the company expects sales to jump to C$6.9 million, which would represent annual growth of 54%. For FY19, the consensus estimate is C$105 million, which would represent growth of 435%. Namaste Technologies (TSXV:N) (OTC: NXTTF) will report financials for its fiscal Q3 ending May 31 by the end of July. It previously reported that it generated sales of C$1.25 million in March. Organigram (TSXV: OGI) (OTC: OGRMF) will report financials for its fiscal Q3 ending May 31 by the end of July. According to Sentieo, analysts expect sales of C$3.81 million, up 78% from a year ago. We continue to expect this list of revenue generating companies to grow and are monitoring for additional companies that meet the qualifications.

Visit the Public Cannabis Company Revenue Tracker to see the complete list of qualifying companies.

Get ahead of the crowd by signing up for 420 Investor, the largest & most comprehensive premium subscription service for cannabis traders and investors since 2013.

Exclusive article by Alan Brochstein, CFA Facebook | LinkedIn | Email Based in Houston, Alan leverages his experience as founder of online communities 420 Investor , the first and still largest due diligence platform focused on the publicly-traded stocks in the cannabis industry. With his extensive network in the cannabis community, Alan continues to find new ways to connect the industry and facilitate its sustainable growth. At New Cannabis Ventures , he is responsible for content development and strategic alliances. Before shifting his focus to the cannabis industry in early 2013, Alan, who began his career on Wall Street in 1986, worked as an independent research analyst following over two decades in research and portfolio management. A prolific writer, with over 650 articles published since 2007 at Seeking Alpha , where he has 70,000 followers, Alan is a frequent speaker at industry conferences and a frequent source to the media, including the NY Times, the Wall Street Journal, Fox Business, and Bloomberg TV. Contact Alan: Twitter